Kiora Pharmaceuticals, Inc. stock is down -18.69% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November. 100% of analysts rate it a buy.
Kiora Pharmaceuticals, Inc. develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.